¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"active immunization"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ªÈ­
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    1. ¿¹¹æÁ¢Á¾, ¸é¿ªÁ¢Á¾ 2. ¸é¿ªÈ­
  • latent immunization
    ÀáÀç¸é¿ªÈ­
  • oral immunization
    °æ±¸¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æ¸é¿ªÁ¢Á¾
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • active
    ´Éµ¿-, Àû±Ø-, Ȱ¼º-
  • active carbon
    Ȱ¼º½¡, Ȱ¼ºÅº
  • active electrode
    Ȱ¼ºÀü±Ø
  • active exercise
    ´Éµ¿¿îµ¿
  • active gradient shielding
    ´Éµ¿°æ»çÂ÷Æó
  • active hyperemia
    ´Éµ¿ÃæÇ÷
  • active imagination
    Àû±Ø»ó»ó, Àû±Ø¸í»ó
  • active immunity
    ´Éµ¿¸é¿ª
  • active incorporative mode
    Àû±ØÇÔÀÔ¾ç½Ä
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    ¿¹¹æÁ¢Á¾, ¸é¿ªÁ¢Á¾, ¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • active carbon
    Ȱ¼º½¡, Ȱ¼ºÅº
  • active immunity
    ´Éµ¿¸é¿ª
  • active material
    Ȱ¼º¹°Áú
  • active oxygen
    Ȱµ¿»ê¼Ò, Ȱ¼º»ê¼Ò
  • active phase
    Ȱ¼º±â
  • active site
    Ȱ¼ººÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ªÈ­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    ¿¹¹æÁ¢Á¾, ¸é¿ªÈ­
  • latent immunization
    ÀáÀç¸é¿ªÈ­
  • oral immunization
    °æ±¸¸é¿ªÈ­
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • active
    ´Éµ¿-, Àû±Ø-, Ȱ¼º-
  • active carbon
    Ȱ¼º½¡, Ȱ¼ºÅº
  • active electrode
    Ȱµ¿Àü±Ø
  • active exercise
    ´Éµ¿¿îµ¿
  • active hydrogen
    Ȱ¼º¼ö¼Ò
  • active hyperemia
    ´Éµ¿ÃæÇ÷
  • active imagination
    Àû±Ø»ó»ó, Àû±Ø¸í»ó
  • active immunity
    ´Éµ¿¸é¿ª
  • active marrow
    Ȱ¼º°ñ¼ö
  • active material
    Ȱ¼º¹°Áú
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization
    ¸é¿ª(¹ý)
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization, passive
    ¼öµ¿¸é¿ª
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • MR active element
    ÀÚ±â°ø¸í Ȱ¼º ¿ä¼Ò
  • MR active nuclei
    ÀÚ±â°ø¸í Ȱ¼º ÇÙ
  • active
    Ȱµ¿¼º(üÀÔÑàõ), ´Éµ¿¼º(ÒöÔÑàõ).
  • active hyperemia
    ´Éµ¿Àû Ç÷·ùÁõ°¡(ÒöÔÑîÜúì×µñòÊ¥)
  • active apperception
    ÀÚµ¿(Àû)Åë°¢(ÀÛ¿ë)(í»ÔÑîÜ÷ÖÊÆíÂéÄ).
  • active carbon
    Ȱ¼ºÅº(üÀàõ÷©).
  • active earth
    Ȱ¼ºÅä(Ì·ËÛ̬).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ª¹ý, ´Éµ¿¸é¿ªÁ¶Ä¡
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • deliberate immunization
    Àΰø¸é¿ª
  • immunization
    ¸é¿ª(¹ý)
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization, passive
    ¼öµ¿¸é¿ª
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(ÌèÏ¢Øóæ¹Ûö).
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(Ë­Ë´ËÎËçËÑ).
  • passive immunization
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹).
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • active
    Ȱµ¿¼º(üÀÔÑàõ), ´Éµ¿¼º(ÒöÔÑàõ).
  • active hyperemia
    ´Éµ¿Àû Ç÷·ùÁõ°¡(ÒöÔÑîÜúì×µñòÊ¥)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • immunization
    Á¢Á¾(ïÈðú)
  • natural immunization
    ÀÚ¿¬Á¢Á¾(í»æÔïÈðú)
  • active acetaldehyde
    Ȱ¼º(üÀàõ) ¾Æ¼¼Æ®¾Ëµ¥ÇÏÀ̵å
  • active acetate
    Ȱ¼º¾Æ¼¼Æ®»ê¿°(ß«ç¤)
  • active acetyl
    Ȱ¼º(üÀàõ)¾Æ¼¼Æ¿
  • active acyl
    Ȱ¼º (üÀàõ)¾Æ½Ç
  • active adenocyl
    Ȱ¼º(üÀàõ) ¾Æµ¥³ë½Ç
  • active adenylate
    Ȱ¼º ¾Æµ¥´Ò»ê¿° (ß«ç¤)
  • active aldehyde
    Ȱ¼º(üÀàõ)¾Ëµ¥ÇÏÀ̵å
  • active aldehyde theory
    Ȱ¼º(üÀàõ)¾Ëµ¥ÇÏÀ̵å·Ð(Öå)
  • active amino acid
    Ȱ¼º(üÀàõ)¾Æ¹Ì³ë»ê (ß«)
  • active anaphylaxis
    Ȱ¼º(üÀàõ)¾Æ³ªÇʶô½Ã½º
  • active carbohydrate
    Ȱ¼º´çÁú (üÀàõÓØòõ)
  • active carbon
    Ȱ¼ºÅº (üÀàõ÷©)
  • active carbon dioxide
    Ȱ¼ºÀÌ»êȭź¼Ò (üÀàõì£ß«ûù÷©áÈ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active
    Ȱµ¿¼º, ´Éµ¿¼º
  • active gradient shielding
    ´Éµ¿°æ»çÂ÷Æó
  • active shielding
    ´Éµ¿Â÷Æó
  • active shimming
    ´Éµ¿º¸Á¤
  • MR active element
    ÀÚ±â°ø¸íȰ¼º¿ä¼Ò
  • MR active nuclei
    ÀÚ±â°ø¸íȰ¼ºÇÙ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AA abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];...
AAROM active assertive range of motion; active-assisted range of motion
AS acetylstrophanthidin; acidified serum; acoustic schwannoma; acoustic stimulation; active sarcoidosis...
ACIP acute canine idiopathic polyneuropathy; Advisory Committee on Immunization Practices [CDC]
DPI daily permissible intake; days post inoculation; dietary protein intake; diphtheria-pertussis immuni...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CII Childhood Immunization Initiative
EPI Expanded Program of Immunization
NID National Immunization Day
NIS National Immunization Survey
A Active
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • immunization
    ¸é¿ª¹ý, ¸é¿ª Á¶Ä¡, ¿¹¹æ Á¢Á¾
    ÇÇ°Ë ´ë»óÀ» ¸é¿ª »óÅ·ΠÇÏ´Â, ¶Ç´Â ¸é¿ªÀ» ȹµæ½ÃŰ´Â ¹æ¹ý.
  • active
    Ȱ¼º, Ȱµ¿¼º, ´Éµ¿¼º
    ÀÛ¿ë, Ȱµ¿, ÇàÀ§¸¦ Ư¡À¸·Î Çϸç, ¼öµ¿ÀûÀÌ ¾Æ´Ñ °Í.
  • active acupuncture locus
    Ȱµ¿¼º °æÇ÷ Á¡
  • active coefficient
    Ȱ¼ºµµ °è¼ö
    ¹°ÁúÀÇ ³óµµ°¡ ³·À» ¶§¿¡ ¹ÝÀÀ·ÂÀº ³óµµ¿¡ ºñ·ÊÇϴµ¥ ³óµµ°¡ ³ô¾ÆÁ³À» ¶§´Â ¹ÝÀÀ·ÂÀÌ °¨¼ÒµÇ°í, ³óµµ¿¡ Ȱµ¿°è¼ö¸¦ °öÇÑ °Í¿¡ ºñ·ÊÇØ¼­ ¹ÝÀÀ·ÂÀÌ ³ªÅ¸³­´Ù.
  • active eruption
    Ȱ¼º ¸ÍÃâ, ´Éµ¿Àû ¸ÍÃâ
    1. ¸Å¸ôµÇ¾î ÀÖ´ø Ä¡¾Æ°¡ »ý¸®ÀûÀ¸·Î ´ëÇÕÄ¡ÀÇ ±³ÇÕ¸é±îÁö ¸ÍÃâÇϰųª ¸ÍÃâµÈ Ä¡¾Æ°¡ ¸¶¸ðµÈ °í°æ¸¸Å­ º¸»óÇϱâ À§ÇØ ¸ÍÃâÇÏ´Â Çö»ó. 2. Ä¡¾Æ°¡ ±³ÇÕÁ¢ÃËÀ» ÀÌ·é ÈÄ, ±³ÇÕÆò¸é ¹æÇâÀ¸·Î ´Éµ¿Àû À̵¿À» º¸ÀÌ´Â °Í.
  • active exercise program
    Àû±ØÀû ¿îµ¿
  • active gradient shielding
    ´Éµ¿ °æ»çÂ÷Æó
  • active hydrogen
    Ȱ¼º ¼ö¼Ò
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • active mandibular opening
    ´Éµ¿ ÇÏ¾Ç °³±¸
    ±æÇ×±Ù
  • active material
    Ȱ¼º ¹°Áú
    È­ÇÐ ¹ÝÀÀ¿¡ À־ Ã˸ÅÀÇ ¹ÝÀÀ ÃËÁø ´É·ÂÀ» Ȱ¼ºÈ­ ½ÃŰ´Â ¹°Áú.
  • active myofascial trigger point
    Ȱµ¿¼º ±Ù¸· ¹ßÅëÁ¡
    ÃËÁøÀ» ÅëÇØ ÀÚ±ØÀ» ÁÖÁö ¾Ê´õ¶óµµ ±¹¼ÒÀûÀ̰ųª ÀüÀÌµÈ ÅëÁõÀ̳ª Áõ»óÀ» ³ªÅ¸³»´Â ±Ù¸· ¹ßÅëÁ¡.
  • active principle
    À¯È¿¼ººÐ
    ¾à¹°ÀÇ È¿°ú¸¦ ºÎ¿©ÇÏ´Â ¾à¹° ÁßÀÇ ¼ººÐ
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
active immunization The production of active immunity.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
anthrax immunization A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the USA was first developed in the 1950s and approved by the Food and Drug Administration for general use in 1970. It is produced by the Michigan Biologic Products Institute of Michigan's Department of Health and is given routinely to veterinarians and others working with livestock. In December, 1997 it was announced that all US military would receive the vaccine, as do the military in the UK and Russia, the reason being concern that anthrax might be used in biologic warfare.
(12 Dec 1998)
german measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (German measles). The MMR vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or MMR vaccination prior to entrance. Most children should receive MMR vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the MMR vaccine. Pregnant women should wait until after delivery before being immunised with MMR. People with HIV or AIDS should normally receive MMR vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
passive immunization The production of passive immunity.
(05 Mar 2000)
measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
chickenpox immunization This vaccine prevents the common disease known as chickenpox (varicella zoster). While chickenpox is often considered a trivial illness, it can cause significant lost time on the job and in school and have serious complications including ear infections, pneumonia, and infection of the rash with bacteria, inflammation of the brain (encephalitis) leading to difficulty with balance and coordination (cerebellar ataxia), damaged nerves (palsies), and Reye's syndrome, a potentially fatal complication. The vaccination requires only one shot given at about a year of age. If an older person has not had chickenpox, the shot may be given at any time. There have been few significant reactions to the chickenpox vaccine. All children, except those with a compromised immune system, should have the vaccination.
(12 Dec 1998)
rubella immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
mumps immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
pneumococcal pneumonia immunization This vaccine, which prevents one of the most common and severe forms of pneumonia, is usually given only once in a lifetime, usually after the age of 55, to someone with ongoing lung problems (such as chronic obstructive pulmonary disease or asthma) or other chronic diseases (including those involving the heart and kidneys). This vaccination would rarely be given to children.
(12 Dec 1998)
polio immunization <virology> The vaccines available for vaccination against polio are opv (oral polio vaccine) and ipv (inactivated polio vaccine).
Opv is still the preferred vaccine for most children. As its name suggests, it is given by mouth.
Ipv, or inactivated polio vaccine is given as a shot in the arm or leg. Infants and children should be given four doses of opv. The doses are given at 2 months, 4 months, 6-18 months and 4-6 years of age.
Persons allergic to eggs or the drugs neomycin or streptomycin should receive opv, not the injectable ipv. Conversely, ipv should be given if the vaccine recipient is on long-term steroid (cortisone) therapy, has cancer, or is on chemotherapy or if a household member has aids or there is an unimmunised adult in the house.
(21 Jun 1999)
haemophilus influenzae type b immunization See HIB immunization,
(12 Dec 1998)
hepatitis a immunization When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain healthcare workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
hepatitis b immunization Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Healthcare workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
hib immunization This vaccine is to prevent disease caused by the haemophilus influenzae type b (hib) bacteria. The h. Influenzae (h. Flu) bacteria can cause a range of serious diseases including meningitis with potential brain damage and epiglottitis with airway obstruction poisoning. The hib vaccine is usually given at 2, 4 and 6 months of age. A final booster is given at 12-15 months of age. Hib vaccine rarely causes severe reactions.
(12 Dec 1998)
dpt immunization DPT immunization protects from diphtheria, pertussis (whooping cough), and tetanus and is given in a series of 5 shots at 2, 4, 6, 18 months of age and 4-6 years of age. Thanks to vaccination programs, these diseases have become less common. However, there are still unvaccinated individuals capable of carrying and passing diphtheria and pertussis to others who are not vaccinated. Tetanus bacteria are prevalent in natural surroundings, such as contaminated soil. See also DTaP immunization.
(12 Dec 1998)
dtap immunization Like DPT, DTaP protects from diphtheria, pertussis (whooping cough) and tetanus. DTaP is the same as DTP, except that it contains only acellular pertussis vaccine which is thought to cause fewer of the minor reactions associated with immunization and is also probably less likely to cause the more severe reactions occasionally seen following pertussis vaccination. DTaP is currently recommended only for the shots given at 18 months and 4-6 years of age.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
active immunization The act of artificially stimulating the body to develop antibodies against infectious disease by the administration of vaccines or toxoids.
Ãâó: www.nbc-med.org/SiteContent/MedRef/OnlineRef/Field...
active immunization a vaccination
Ãâó: www.equinekingdom.com/data/horse_glossary/a_terms....
active immunization the administration of a vaccine or toxoid which causes an immunologic response involving production of specific antibody or antitoxin.
Ãâó: www.accessexcellence.org/AE/AEC/CC/vaccine_glossar...
active immunization The administration of a vaccine to stimulate the host immune system to develop immunity (protection) against a specific pathogen or toxin. As of January 1999, vaccines are available for the following potential biological warfare agents: anthrax, Argentine hemorrhagic fever, botulinum toxin, plague, Q fever, Rift Valley Fever, smallpox, tularemia, Venezuelan equine encephalitis (VEE), and yellow fever. See also chemoprophylaxis; immunization.
Ãâó: www.merrea.org/glossary.html
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • active
    Ȱµ¿ÀûÀÎ
  • active
    Ȱµ¿ÀûÀÎ;Àû±ØÀûÀÎ;Èû¼¾;´Éµ¿ÀÇ
  • immunization
    ¸é¿ª(¹ý);¸é¿ªÁ¶Ä¡;¸éÁ¦;(¸é¿ª)¿¹¹æÁÖ»ç
  • passive immunization
    ¼öµ¿ ¸é¿ª
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á